ISIS

Isis Pharmaceuticals, Inc. Press Releases

$39.58
*  
0.43
1.07%
Get ISIS Alerts
*Delayed - data as of Aug. 27, 2014  -  Find a broker to begin trading ISIS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    ISIS After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
8/15/2014 7:00:00 AM - PR Newswire

Isis Reports Financial Results and Highlights for Second Quarter 2014
8/4/2014 8:30:00 AM - PR Newswire

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
8/1/2014 7:00:00 AM - PR Newswire

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
7/28/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)
7/17/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
7/16/2014 7:00:00 AM - PR Newswire

Biotech Equities Technical Momentum -- Research on Organovo, Prana Biotechnology, Isis Pharma, and Pharmacyclics
7/14/2014 7:04:00 AM - PR Newswire

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program
7/2/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR Rx
6/24/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec
6/17/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes
6/16/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals to Present at the 2014 Wells Fargo Healthcare Conference
6/12/2014 7:00:00 AM - PR Newswire

Stock Watchout on Biotech Industry -- Research on Isis Pharma, Pharmacyclics, Amarin, and Prana Biotechnology
6/11/2014 7:10:00 AM - PR Newswire

Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-GCGR Rx Phase 2 Data Presented at the 2014 ADA Scientific Sessions
6/11/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Earns $15 Million from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx
6/10/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1
6/9/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals to Present at The Goldman Sachs 35th Annual Global Healthcare Conference
6/4/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals to Present a General Corporate Update at its 2014 Annual Meeting of Stockholders and Open House
6/3/2014 7:00:00 AM - PR Newswire